Teads Holding Co.

(a) As previously reported, Jason Kiviat will cease serving as our CFO effective November 10, 2026, at which point Michael Coyle will assume the role. In connection with Mr. Kiviat’s transition from the CFO role, the Company entered into a separation and transition agreement with Mr. Kiviat (the “Agreement”), dated November 9, 2026, pursuant to which Mr. Kiviat, after ceasing to serve as our CFO, will continue as a senior advisor providing transition services through his separation from employment with the Company, which is expected to occur on June 30, 2027. While employed by the Company, Mr. Kiviat will continue to receive his base salary and his outstanding equity awards will vest on their ordinary schedule.

The Company has continued to focus on strengthening its balance sheet, and with the volatility in our business, the Company is also focused on maintaining appropriate levels of liquidity as it executes on strategic initiatives and cost reduction measures to optimize operations. Mr. Kiviat was instrumental in designing, structuring and executing on our $125.0 million non-recourse accounts receivable financing facility (the “A/R Facility”), which closed on September 30, 2026. Further, Mr. Kiviat’s support in transitioning the CFO role is expected to be beneficial to the Company. In recognition of Mr. Kiviat’s role in the consummation of the A/R Facility and the Company’s desire to continue to benefit from Mr. Kiviat’s services, under the Agreement, Mr. Kiviat will be paid a one-time bonus of $250,000 to be paid following his cessation of service as CFO, which is subject to an after-tax clawback if Mr. Kiviat resigns prior to June 30, 2027. Further, if Mr. Kiviat’s employment is terminated by the Company without cause prior to June 30, 2027, then Mr. Kiviat would receive his base salary and continued health insurance benefits through June 30, 2027. The Agreement includes a release of claims from Mr. Kiviat and acknowledgement of his restrictive covenant obligations.

(b) None.

(c) During the three months ended September 30, 2026, none of the Company’s directors or executive officers adopted orterminated any contract, instruction, or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.